Investors who bought Phreesia stock between May 8, 2025 and March 30, 2026 have until July 13, 2026 to ask a court to make them lead plaintiff in a securities class action against the company. The Rosen Law Firm, which issued the reminder, says a class action has already been filed.
Phreesia trades on the New York Stock Exchange under the ticker PHR. The lawsuit claims that throughout the class period, the company and its executives made false or misleading statements, or hid adverse facts, about slowing demand and reduced visibility in key revenue streams. It singles out weakened pharmaceutical marketing commitments in the Network Solutions segment. According to the suit, investors lost money when the true picture reached the market.
Those are allegations. The notice does not report any finding by a court.
What the lead plaintiff does
A lead plaintiff is a representative party who directs the litigation on behalf of other class members. Anyone who wants that role must file a motion with the court by the July 13 deadline.
Rosen says no class has been certified. Until one is, investors are not represented by counsel unless they hire a lawyer, and they may choose their own. They can also stay on as absent class members and do nothing for now. The firm says an investor’s ability to share in any future recovery does not depend on serving as lead plaintiff.
The firm says it works on a contingency fee arrangement, so shareholders who qualify would pay no out-of-pocket fees or costs. Investors can join through the firm’s website or by calling Phillip Kim toll-free at 866-767-3653.
Rosen also used the notice to make its own case for hiring it. It says it concentrates on securities class actions and shareholder derivative litigation, and that the firm secured more than $438 million for investors in 2019 alone. It warns that some firms issuing notices are middlemen who refer clients to the lawyers who actually litigate.
